Published in Hepatology on March 01, 2003
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH) | NCT00845845
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med (2007) 2.93
Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.89
Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials (2008) 2.17
Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia (2009) 2.03
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg (2005) 1.70
NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver (2012) 1.70
Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol (2009) 1.68
High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J (2009) 1.63
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology (2009) 1.59
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials (2009) 1.48
Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol (2008) 1.43
Liver-specific beta-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol (2009) 1.23
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Treatment of non-alcoholic fatty liver disease. Ther Clin Risk Manag (2007) 1.18
PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res (2010) 1.11
Similarities and differences in the pathogenesis of alcoholic and nonalcoholic steatohepatitis. Semin Liver Dis (2009) 1.08
Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev (2011) 1.07
The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut (2006) 0.98
Chronic oxidative stress sensitizes hepatocytes to death from 4-hydroxynonenal by JNK/c-Jun overactivation. Am J Physiol Gastrointest Liver Physiol (2009) 0.98
Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab (2010) 0.98
Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal (2011) 0.96
Hepatic steatosis: a benign disease or a silent killer. World J Gastroenterol (2008) 0.92
Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients (2015) 0.92
Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92
Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2011) 0.91
Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg (2010) 0.91
DNA damage response and sphingolipid signaling in liver diseases. Surg Today (2015) 0.90
What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol (2012) 0.89
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol (2012) 0.86
Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev (2014) 0.85
Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal (2014) 0.84
A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. Toxicol Appl Pharmacol (2015) 0.82
The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr (2015) 0.82
A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH. J Clin Biochem Nutr (2009) 0.82
The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol (2014) 0.81
Pharmacokinetics of Antimicrobials in Obese Children. GaBI J (2013) 0.80
Effects of dietary inulin, statin, and their co-treatment on hyperlipidemia, hepatic steatosis and changes in drug-metabolizing enzymes in rats fed a high-fat and high-sucrose diet. Nutr Metab (Lond) (2012) 0.80
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats. Acta Pharmacol Sin (2012) 0.79
Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol (2005) 0.79
Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep (2014) 0.79
Regulation of the effects of CYP2E1-induced oxidative stress by JNK signaling. Redox Biol (2014) 0.78
Treatment of Nonalcoholic Fatty Liver Disease. Curr Treat Options Gastroenterol (2003) 0.78
A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol (2007) 0.77
Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases. Curr Mol Pharmacol (2015) 0.77
Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH). Hepatobiliary Surg Nutr (2015) 0.77
Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther (2015) 0.77
Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab Dispos (2012) 0.76
CYP2E1 autoantibodies in liver diseases. Redox Biol (2014) 0.76
Identification of cytochrome CYP2E1 as critical mediator of synergistic effects of alcohol and cellular lipid accumulation in hepatocytes in vitro. Oncotarget (2015) 0.75
Schisandrin B: A Double-Edged Sword in Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev (2016) 0.75
Mimp/Mtch2, an Obesity Susceptibility Gene, Induces Alteration of Fatty Acid Metabolism in Transgenic Mice. PLoS One (2016) 0.75
Study of the effects of monacolin k and other constituents of red yeast rice on obesity, insulin-resistance, hyperlipidemia, and nonalcoholic steatohepatitis using a mouse model of metabolic syndrome. Evid Based Complement Alternat Med (2012) 0.75
Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice. J Nutr Biochem (2016) 0.75
Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol (2015) 0.75
Toxicological Implications of Mitochondrial Localization of CYP2E1. Toxicol Res (Camb) (2017) 0.75
Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res (2017) 0.75
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology (2005) 2.72
Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem (2002) 2.61
The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology (2004) 2.50
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology (2002) 2.26
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab (2008) 1.79
Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver. Am J Physiol Gastrointest Liver Physiol (2004) 1.78
Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem (2003) 1.78
Reproducibility of oligonucleotide arrays using small samples. BMC Genomics (2003) 1.75
Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J (2005) 1.71
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
GLM-beamformer method demonstrates stationary field, alpha ERD and gamma ERS co-localisation with fMRI BOLD response in visual cortex. Neuroimage (2005) 1.35
Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element-binding proteins. Alcohol (2004) 1.29
Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 1.28
Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos (2006) 1.27
Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos (2006) 1.26
Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res (2006) 1.23
Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer (2008) 1.18
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer (2010) 1.18
Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels. Am J Physiol Gastrointest Liver Physiol (2010) 1.18
The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther (2003) 1.13
Noninvasive positive-pressure ventilation: An experimental model to assess air and particle dispersion. Chest (2006) 1.13
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol (2003) 1.11
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos (2009) 1.11
The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther (2003) 1.10
Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol (2003) 1.08
Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med (2007) 1.08
Association between the CYP3A5 genotype and blood pressure. Hypertension (2004) 1.07
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04
Living kidney donor follow-up in a dedicated clinic. Transplantation (2005) 1.04
Global effects of vitamin A deficiency on gene expression in rat liver: evidence for hypoandrogenism. J Nutr Biochem (2005) 1.04
Sustained neuronal activity generated by glial plasticity. J Neurosci (2011) 1.03
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther (2006) 1.02
The influence of L-glutamine on the depression of hepatic cytochrome P450 activity in male rats caused by total parenteral nutrition. Drug Metab Dispos (2002) 1.01
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos (2009) 0.99
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS (2008) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.98
Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am J Physiol Gastrointest Liver Physiol (2011) 0.97
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos (2004) 0.96
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol (2006) 0.95
Literature mining on pharmacokinetics numerical data: a feasibility study. J Biomed Inform (2009) 0.93
In vivo real-time 3-D intracardiac echo using PMUT arrays. IEEE Trans Ultrason Ferroelectr Freq Control (2014) 0.92
Relationship between alcohol drinking and aspartate aminotransferase:alanine aminotransferase (AST:ALT) ratio, mean corpuscular volume (MCV), gamma-glutamyl transpeptidase (GGT), and apolipoprotein A1 and B in the U.S. population. J Stud Alcohol Drugs (2010) 0.92
Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition. Drug Metab Dispos (2008) 0.91
A general linear model for MEG beamformer imaging. Neuroimage (2004) 0.91
Innate differences in protein expression in the nucleus accumbens and hippocampus of inbred alcohol-preferring and -nonpreferring rats. Proteomics (2003) 0.91
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg (2013) 0.90
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase. Drug Metab Dispos (2012) 0.89
Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest (2007) 0.89
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochem Pharmacol (2012) 0.88
Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos (2005) 0.88
Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am J Gastroenterol (2005) 0.88
Olfactory system activation from sniffing: effects in piriform and orbitofrontal cortex. Neuroimage (2004) 0.88
Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos (2002) 0.88
Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2003) 0.88
Relationship among alcohol intake, body fat, and physical activity: a population-based study. Ann Epidemiol (2010) 0.88
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption: a comparison with nonalcoholics. Hepatology (2005) 0.87
An unusual case of central diabetes insipidus & hyperglycemic hyperosmolar state following cardiorespiratory arrest. BMC Res Notes (2013) 0.87
The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol (2002) 0.87
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology (2006) 0.86
Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution. J Chem Inf Model (2013) 0.86
A new probabilistic rule for drug-dug interaction prediction. J Pharmacokinet Pharmacodyn (2009) 0.86
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos (2005) 0.85
Insulin sensitivity is preserved despite disrupted endothelial function. Am J Physiol Endocrinol Metab (2006) 0.85
A proteomic workflow for discovery of serum carrier protein-bound biomarker candidates of alcohol abuse using LC-MS/MS. Electrophoresis (2009) 0.85
Airflow and droplet spreading around oxygen masks: a simulation model for infection control research. Am J Infect Control (2007) 0.85
Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans. J Neurosci (2013) 0.85
Alcoholic myopathy and acetaldehyde. Novartis Found Symp (2007) 0.84
Quantification of vincristine and its major metabolite in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Ther Drug Monit (2008) 0.84
Ethanol metabolism by HeLa cells transduced with human alcohol dehydrogenase isoenzymes: control of the pathway by acetaldehyde concentration. Alcohol Clin Exp Res (2011) 0.84
Effect of cirrhosis and liver transplantation on the gender difference in QT interval. Am J Cardiol (2005) 0.83
Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase. Arch Biochem Biophys (2009) 0.83